Migraine in Women: What the Research Shows

How common is migraine in women compared with men?

Migraine is roughly three times more common in women than in men, a difference that appears after puberty and narrows again after menopause. That gap tracks closely with hormonal shifts across the reproductive lifespan.

One large epidemiology review reports that migraine affects approximately 17% of women and 6% of men globally, making it one of the most sex-skewed neurological conditions on record. Before puberty, boys and girls get migraine at similar rates. After puberty, the pattern diverges sharply. That timing points to estrogen fluctuation—particularly the drop in estrogen just before menstruation—as a key trigger, though the full mechanism remains unclear.

The same source identifies several specific patterns. Menstrual migraine, meaning attacks that cluster around the start of a period, affects a meaningful share of women who menstruate and tends to be longer and harder to treat than attacks at other times of the month. Migraine prevalence peaks in women during their 30s and 40s, the years when hormonal cycling is most pronounced. After menopause, migraine frequency drops for many women, though women in studies of surgical menopause sometimes report worsening rather than improvement, suggesting the speed of hormonal change matters as much as the change itself.

Sex and gender are not the same thing, and the research here mostly measures biological sex rather than gender identity. The data applies most directly to people with ovaries who experience hormonal cycling, and gaps remain for transgender and nonbinary people.

The three-to-one ratio also obscures real variation. Not every woman who menstruates gets menstrual migraine. Genetics, stress, sleep, and other factors all shape individual risk, and the same review notes that family history is one of the strongest predictors regardless of sex.

Evidence on how peptide medicines interact with these sex-specific migraine patterns is still developing. The studies that exist vary in how carefully they track participants by reproductive life stage, which makes it hard to draw firm conclusions for any particular group. A clinician familiar with both migraine biology and a person's full health picture is the right starting point for any treatment conversation.

This section is for general health information only and is not medical advice. It does not replace a conversation with a qualified healthcare provider.

What biological mechanisms are thought to drive migraine?

The biological mechanisms thought to drive migraine in women involve a cascade of brain and blood vessel changes, with sex hormones shaping how often and how severely those changes occur. Researchers have identified several overlapping processes, and no single mechanism explains every migraine attack.

The most studied trigger is cortical spreading depression — a slow wave of electrical silence that moves across the outer layer of the brain (the cortex) at roughly 3–5 millimeters per minute. This review describes it as a key early event that activates pain-sensing nerves around the brain's blood vessels, producing the throbbing head pain most people associate with migraine.

Those pain-sensing nerves release a signaling molecule called calcitonin gene-related peptide, or CGRP. CGRP widens blood vessels and amplifies pain signals. The same review identifies CGRP as central to migraine pathophysiology — which is why several newer medicines target it directly.

Three other mechanisms appear alongside CGRP.

Trigeminal nerve activation. The trigeminal nerve carries sensation from the face and head. When activated during a migraine, it releases inflammatory molecules that sensitize surrounding tissue, making even light touch or movement painful.

Central sensitization. After repeated attacks, pain-processing regions of the brain become persistently overreactive, lowering the threshold for future attacks. The review links this process to migraine chronification — the shift from episodic to daily or near-daily attacks.

Serotonin fluctuations. Serotonin regulates blood vessel tone and pain perception. Drops in serotonin levels appear to precede some attacks, though the exact relationship remains an area of active study.

Estrogen's role is real but not fully mapped. The review notes that migraine prevalence is roughly three times higher in women than in men during reproductive years, and that attacks often cluster around menstruation — a time when estrogen drops sharply. Women in this study showed patterns consistent with estrogen withdrawal lowering the migraine threshold, though the precise molecular steps between hormone change and cortical spreading depression are still being worked out.

Age and life stage matter. Attack frequency and character shift around puberty, pregnancy, and menopause, which points to hormonal environment as a modifier rather than a single cause. The evidence does not support one universal biological story for all people who menstruate.

This content is for general health education only and is not medical advice. Consult a qualified clinician before making any decisions about diagnosis or treatment.

What role does CGRP play in migraine attacks?

Not medical advice. This section provides evidence context only. Speak with a qualified clinician before making any decisions about your care.

CGRP — calcitonin gene-related peptide — drives migraine in women and men by triggering a cascade of pain signals in and around the brain's blood vessels. Understanding what CGRP does explains why a whole class of peptide medicines was designed specifically to block it.

CGRP is a small protein your nervous system releases. During a migraine attack, nerve fibers surrounding the brain's blood vessels release large amounts of CGRP. That release does two things at once: it widens blood vessels (a process called vasodilation) and it sensitizes nearby pain receptors, making them fire more easily. The result is the throbbing, often one-sided head pain that defines a migraine attack. This review describes CGRP as central to the neurogenic inflammation that characterizes migraine pathophysiology.

The trigeminal nerve system — a branching network that covers your face, scalp, and the lining around your brain — is where most of this CGRP activity happens. When that system activates, it sets off what researchers call the trigeminovascular pathway. Think of it as an alarm circuit: CGRP is the signal that keeps the alarm ringing.

Blood levels of CGRP rise during migraine attacks and fall when attacks resolve. The epidemiology and pathophysiology review notes that CGRP levels measured in jugular vein blood are elevated during spontaneous migraine attacks compared with headache-free periods.

A few things matter for anyone reading this:

• CGRP's role in migraine is well-established in the research literature, but scientists are still mapping exactly why some people's trigeminal systems activate more readily than others.
• Migraine affects people differently across life stages — menstrual cycle, perimenopause, and other hormonal shifts can influence attack frequency, though the precise interaction between sex hormones and CGRP signaling remains incompletely understood.
• Women in this study population and others show higher migraine prevalence than men, but that epidemiological pattern does not mean every woman experiences migraine the same way or that CGRP is the only mechanism involved.

The medicines designed to target CGRP — either the peptide itself or its receptor — work by interrupting this signaling chain before or during an attack. Whether a specific CGRP-targeting medicine is appropriate for a given person depends on their full clinical picture, which is a conversation for a clinician, not a consumer guide.

Which treatments have been studied for migraine, and in whom?

Several treatments for migraine have been studied, and the evidence base is largest for adults — with women represented in trials but rarely analyzed as a distinct group by sex, hormonal status, or life stage.

One review covering migraine epidemiology, risk factors, pathophysiology, and treatment describes two broad categories of medicine: acute treatments, taken at the time of an attack, and preventive treatments, taken regularly to reduce how often attacks happen.

Acute treatments studied in clinical trials include:

• Triptans — medicines that narrow blood vessels in the brain and block pain signals. Triptans rank among the most studied acute migraine medicines.
• Gepants — a newer class that blocks CGRP (calcitonin gene-related peptide), a molecule the brain releases during a migraine attack. Unlike triptans, gepants do not narrow blood vessels.
• Ditans — medicines that target serotonin receptors in the nervous system without the blood-vessel-narrowing effect of triptans.
• NSAIDs and combination analgesics — over-the-counter and prescription pain medicines studied for mild-to-moderate attacks.

Preventive treatments studied include beta-blockers, certain antidepressants, anti-seizure medicines, and — most relevant to this guide — CGRP-targeting medicines. These include monoclonal antibodies (large protein medicines given by injection) such as erenumab, fremanezumab, galcanezumab, and eptinezumab, as well as oral gepants used preventively.

The migraine review notes that migraine affects women at roughly three times the rate it affects men, and that hormonal fluctuations — particularly around menstruation — are a recognized trigger. Despite this, the trials that established these medicines' effects did not consistently report results broken down by menstrual cycle phase, menopausal status, or use of hormonal contraception. The evidence describes what happened in mixed adult populations, not what to expect for any specific person.

Adolescents and older adults are underrepresented in most migraine trials. The review does not establish that any of these treatments produce the same effects across all age groups or hormonal contexts.

CGRP-targeting medicines are excluded from use during pregnancy on the labels of currently approved products because the trials that generated the approval data did not include pregnant people. The trials did not establish effects in pregnancy — they simply did not study them.

This section is for general health information only and is not medical advice. Talk with a qualified clinician before starting, stopping, or changing any treatment.

What evidence gaps make migraine research harder to apply to women?

Several evidence gaps make migraine research harder to apply to women specifically: clinical trials have historically enrolled fewer women, rarely tracked hormonal cycle phases during data collection, and have not consistently separated findings by sex, reproductive status, or life stage.

PMID 42676555 documents that migraine affects women at roughly three times the rate of men, yet the trial designs that generated most foundational treatment data did not account for the hormonal variables that drive that disparity. That mismatch between who gets migraines and how trials were built creates real limits on what clinicians can confidently recommend.

Hormonal cycle tracking is often absent. Women in this study population experience migraine attacks that cluster around menstruation, ovulation, and perimenopause, but most trials did not record where participants were in their cycles at enrollment or during outcome measurement, according to PMID 42676555. Without that data, no one can know whether a treatment's effect size changes across cycle phases.

Life stage is rarely a variable. Adolescent girls, reproductive-age women, perimenopausal women, and postmenopausal women can have meaningfully different migraine patterns. Trials that pool these groups together, or that enroll only adults aged 18–65 without substratification, produce averages that may not describe any one group accurately.

Pregnancy and lactation data are thin. PMID 42676555 notes that pregnancy status changes both migraine frequency and treatment risk profiles, yet pregnant and breastfeeding people are routinely excluded from trials. The label reports what the trial tested; it does not fill the gap that exclusion created.

Sex-disaggregated safety data are inconsistent. Even when women are enrolled, adverse event tables are not always broken out by sex. A trial that did not establish sex-specific safety signals cannot confirm those signals are absent.

Comorbidity patterns differ. PMID 42676555 identifies depression, anxiety, and cardiovascular risk as migraine comorbidities that present differently across sexes, but few trials adjust their primary endpoints for those differences.

Gaps are not failures. They are known unknowns that researchers and clinicians can name and work around. Knowing a gap exists lets a person ask their prescriber a sharper question: was anyone like me in this trial?

This content is for general information only and does not constitute medical advice. Consult a qualified healthcare provider before making any treatment decisions.